Transmedics Group (TMDX) Hisse Fiyat
Transmedics Group Fiyat
Gelir, son 9 yılda yıllık bileşik %66,3 artarak 605,49 M USD seviyesine ulaştı. Transmedics Group şirketinde net marj %31,4 seviyesinde bulunuyor; birkaç yıl önceki %-146,1 seviyesine göre yükseldi. Analistler 95,00 USD medyan fiyat hedefi belirliyor; bu, güncel fiyatın %30,6 üzerinde bir seviyeye işaret ediyor. 19 analistten 14 tanesi hisse için alım öneriyor — genel konsensüs: Al.
Transmedics Group hisse senedi fiyatı
Bu verilere Eulerpool API üzerinden ulaşın
Ayda 100.000 ücretsiz istek · kredi kartı yok
Transmedics Group iş modeli ve hisse analizi
Transmedics Group hakkında sık sorulan sorular
Transmedics Group Inc. operates under a business model focused on the development and commercialization of organ transplant solutions. The company specializes in designing and producing innovative medical devices and systems that preserve, monitor, and assess organs intended for transplantation. By harnessing cutting-edge technology, Transmedics' business model aims to improve both donor organ quality and transplantation outcomes. Through its offerings, the company seeks to address critical challenges faced by organ transplant patients and healthcare professionals worldwide. Transmedics Group Inc. continues to drive innovation in the organ transplant field through its comprehensive product portfolio and commitment to advancing patient care.
Transmedics Group Inc is primarily active in the biomedical industry.
The main competitors of Transmedics Group Inc in the market include Medtronic, Inc., XVIVO Perfusion AB, and OrganAssist BV.
Transmedics Group Inc is a leading medical technology company specializing in organ transplant solutions. Founded in 1998, the company has been dedicated to improving outcomes for patients awaiting organ transplants. With its groundbreaking Organ Care System (OCS), Transmedics revolutionized the field by allowing organs to be preserved and assessed outside the traditional cold storage method. This breakthrough technology ensures organs remain at the optimal physiological condition, significantly increasing the chances of successful transplants. Transmedics is committed to continuing innovation and expanding its global presence to address the critical need for organ transplantation worldwide.
Transmedics Group Inc has achieved several significant milestones. Notably, the company successfully developed the Organ Care System (OCS), a breakthrough technology that allows for the preservation and transportation of donor organs. The OCS has revolutionized the field of transplant medicine by extending the time organs can remain outside the body, increasing the chances of successful transplantation. Additionally, Transmedics Group Inc received regulatory approvals for the OCS in major markets, including the United States and Europe. These achievements have solidified the company's position as a leader in the advancement of organ transplantation, benefiting countless patients worldwide.
Transmedics Group Inc is primarily present in the United States.
Transmedics Group Inc represents a commitment to innovation and improving organ transplant outcomes. The company's corporate philosophy centers around its Organ Care System (OCS) technology, which enables the preservation and assessment of donated organs for transplantation. Transmedics Group Inc values the advancements made in organ transplantation, aiming to improve patient outcomes and increase the number of viable organs available for transplant. By leveraging their OCS technology, the company strives to address the critical organ shortage challenge and revolutionize the transplantation field. Through their dedication to innovation and patient-centric approach, Transmedics Group Inc constantly aims to make a positive impact in the field of organ transplantation.
Analistler şu anda Transmedics Group hissesi için ortalama 96,86 USD hedef fiyat belirliyor (medyan: 95,00 USD); bu, son fiyata göre +43,8 % anlamına gelir. Konsensüs 19 analist notuna dayanır.
19 analist şu anda Transmedics Group hissesini değerlendiriyor: 14 al, 5 tut, 0 sat öneriyor. 2026 için analistler Transmedics Group şirketinin 743,61 M USD gelir ve 1,22 USD hisse başına kâr üretmesini bekliyor.
Güncel döviz kuruyla Transmedics Group hissesi 64,75 EUR (72,75 USD) seviyesindedir.
Transmedics Group hissesi (TMDX) 3 borsada işlem görür, bunlar arasında: NASDAQ (TMDX), Frankfurt (8T8.F), München (8T8.MU).
The Transmedics Group Inc is a leading provider of advanced organ care systems for transplantation medicine. The company offers an innovative platform that allows organs to be obtained, protected, transported, and transplanted outside of the body. The company is divided into three main business areas: 1. Organ Care System The Organ Care System (OCS) is a groundbreaking technology that revolutionizes organ care and transplantation. It is a portable, modular system that enables doctors to obtain and protect donor organs outside of the body. The OCS was developed to increase the survival rate of donor organs and reduce the number of transplant rejections. 2. Organ Transport & Storage Solutions The company offers a variety of organ transport and storage solutions that meet the needs of customers. The transport and storage systems are FDA-certified and provide optimal conditions for successful transplantation. 3. Organ Care Services Organ Care Services (OCS) are a key part of Transmedics' business operations. The company offers a wide range of services tailored to the specific needs of customers. These include organ storage, preparation for transplantation, and support during surgeries. Transmedics is an innovative company protected by a number of patents and intellectual property. The company heavily invests in research and development and stays at the forefront of technology to maintain its position as a leader in organ transplantation. In summary, Transmedics Group Inc is a pioneer in the field of organ transplantation. With its offering of advanced organ care systems, the company has revolutionized transplantation medicine and established itself as a leading provider. Transmedics is well-positioned to continue growing and meeting the needs of its customers while helping to save lives.
beklenen'nin Transmedics Group hasılatı 743,61 M USD'dir. Bu rakam, mevcut finansal verilere dayanmakta ve şirketin iş performansını yansıtmaktadır.
beklenen'nin Transmedics Group karı 50,08 M USD'dir. Net kar, tüm giderleri düştükten sonra şirketin kârlılığını gösterir.
Transmedics Group'nin Fiyat/Kazanç (F/K) oranı şu anda 59,46'dir. F/K oranı, cari hisse fiyatını hisse başına kazançla karşılaştırır ve yatırımcıların Transmedics Group hisse senedinin değerlemesini değerlendirmelerine yardımcı olur.
Transmedics Group'nin Fiyat/Satış (F/S) oranı şu anda 4,00'dir. F/S oranı, pazar kapitalizasyonunu yıllık gelirle karşılaştırır ve Transmedics Group hisse senedinin değerleme metriği olarak hizmet eder.
Transmedics Group'nin Eulerpool Kalite Puanı 6/10'dur.
Transmedics Group'nin ISIN'i US89377M1099'dir. ISIN (Uluslararası Menkul Kıymetler Kimlik Numarası), menkul kıymetler için küresel olarak benzersiz bir tanımlayıcıdır.
Transmedics Group'nin WKN'i A2PH5P'dir. WKN (Wertpapierkennnummer), menkul kıymetleri tanımlamak için kullanılan altı haneli bir Alman kimlik numarasıdır.
Transmedics Group'nin ticker'ı TMDX'dir. Ticker sembolü, Transmedics Group hisseleri borsada işlem görmek için kullanılır.
Transmedics Group Hissesi
Transmedics Group Emsaller Grubu
Transmedics Group Ticker
Transmedics Group FIGI
Transmedics Group'nin tüm temel göstergeleri ve derinlemesine analizi
Transmedics Group hissesine yönelik aktienanalizimiz, satış, kar, P/E oranı, P/S oranı, EBIT gibi önemli mali kriterleri içermekte olup, dividende bilgilerini de ele almaktadır. Ayrıca, hisseler, piyasa değeri, borçlar, özsermaye ve Transmedics Group şirketin yükümlülükleri gibi konuları incelemekteyiz. Bu konular hakkında daha detaylı bilgilere ihtiyacınız varsa, web sitemizin alt sayfalarında kapsamlı analizler sunuyoruz: